Eastern Hepatobiliary Surgery Hospital
114
12
14
37
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
2.6%
3 terminated/withdrawn out of 114 trials
92.5%
+6.0% vs industry average
11%
12 trials in Phase 3/4
3%
1 of 37 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (114)
Research on Post-Stroke Anticoagulation Strategies for Atrial Fibrillation Based on Left Atrial Appendage Flow Velocity Measured by Intracardiac Echocardiography (ICE)
Role: collaborator
Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer
Role: lead
HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC
Role: lead
A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma
Role: lead
A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Biliary Tract Cancers
Role: lead
A Trial of Behavioral Intervention on Prognostic Survival of Patients With Unresectable Liver Cancer
Role: lead
The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD
Role: lead
A Study of TIL in Advanced Solid Tumors (DFGD)
Role: collaborator
Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC
Role: collaborator
Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
Role: collaborator
Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
Role: collaborator
A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma
Role: lead
QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors
Role: lead
Bile Omics for Diagnosing Indeterminate Biliary Strictures
Role: collaborator
Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC
Role: collaborator
Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data
Role: collaborator
Dynamic Prediction Model for Patients with Unresectable Biliary Malignancies Receiving Systemic Chemotherapy Combined with Immunotherapy: a Multicenter, Observational Study
Role: collaborator
Comparative Effectiveness Between Indomethacin and Pancreatic Stenting in the Prevention of Post ERCP Pancreatitis
Role: collaborator
Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer
Role: lead
Comparison of Dual-lumen Catheter-guided Mini-forceps Biopsy and Brush Cytology with Vacuum Aspiration in Suspicious Biliary Strictures
Role: collaborator